Gilead pays $7.8bn to take full control of promising multiple myeloma therapy

2026-03-09 13:13:35

Abstract generation in progress

Gilead Sciences is acquiring Arcellx for $7.8 billion to gain full ownership of anito-cel, a promising CAR T-cell therapy for multiple myeloma. The deal, which includes a contingent value right, aims to integrate the drug with a potential FDA approval by late 2026, boosting Gilead’s earnings from 2028. This move strengthens Gilead’s position in advanced multiple myeloma treatments and its CAR T-cell technology platform.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes